Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A pharmaceutical composition is provided which contains a phospholipid-containing composition which antagonizes toll-like receptors 1, 2, 3, 6, 7, 8 and 10. The phospholipid-containing composition consists of regioisomers and stereoisomers of palmitoyloleoylphosphatidylglycerol (POPG) consisting of at least 80% of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof, and no more than 20% of its regioisomer 1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(T-rac-glycerol) or a salt thereof. The phospholipid-containing composition also has enantiomeric enrichment with at least 51% of the dextro rotatory isomer at the sn-2 position of the terminal glycerol moiety.

A pharmaceutical composition is provided which contains a phospholipid-containing composition which antagonizes toll-like receptors 1, 2, 3, 6, 7, 8 and 10. The phospholipid-containing composition consists of regioisomers and stereoisomers of palmitoyloleoylphosphatidylglycerol (POPG) consisting of at least 80% of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof, and no more than 20% of its regioisomer 1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(T-rac-glycerol) or a salt thereof. The phospholipid-containing composition also has enantiomeric enrichment with at least 51% of the dextro rotatory isomer at the sn-2 position of the terminal glycerol moiety.

Some embodiments disclosed herein relate to a composition containing an effective amount of dietary nutrients. In some embodiments, ingestion of the composition provides one or more of the following benefits, or others, improved functioning of an environmentally stressed eye, increased tear flow from the lacrimal glands, improved quality of the lipid secretion from the meibomian glands (e.g., to improve tear breakup time), and augmented DHA fatty acid in the retina damaged by blue light. In some embodiments, the composition is configured to scavenge free radicals in the eye to prevent premature degradation of the visual functions.

Some embodiments disclosed herein relate to a composition containing an effective amount of dietary nutrients. In some embodiments, ingestion of the composition provides one or more of the following benefits, or others, improved functioning of an environmentally stressed eye, increased tear flow from the lacrimal glands, improved quality of the lipid secretion from the meibomian glands (e.g., to improve tear breakup time), and augmented DHA fatty acid in the retina damaged by blue light. In some embodiments, the composition is configured to scavenge free radicals in the eye to prevent premature degradation of the visual functions.